Ticker: BIIB

Company Overview Biogen Inc. (NASDAQ: BIIB) is a leading biopharmaceutical company focused on making innovative therapies for serious diseases including Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), and Alzheimer's. The company's revenues and operations are significantly impacted by the...

Biogen Inc. (NASDAQ: BIIB) - Q1 2025 Financial Overview Biogen reported a total revenue of $2.431 billion for the first quarter of 2025, a 6.1% increase from $2.291 billion in the same period last year. Notably, product revenue was $1.727 billion, up just 0.9% from $1.712 billion. However, the co...

The FDA has approved Eli Lilly's (NYSE: LLY) new Alzheimer's treatment, Kisunla, for early-stage patients, marking it as the second therapy in the U.S. to slow Alzheimer's progression. Priced at $32,000 annually, Kisunla is expected to achieve over $5 billion in peak sales.